Name: ANIP Income Statement - Ani Pharmaceuticals Revenue & EPS | Ledgeburg
Creator: Ledgeburg
License: https://creativecommons.org/licenses/by/4.0/
Keywords: Revenue, Cost of Revenue, Gross Profit, Operating Expenses, Operating Income, Net Income, EPS Basic, EPS Diluted

JavaScript is disabled. Some features may not work properly. For the best experience, please enable JavaScript in your browser.

ANIP - Ani Pharmaceuticals Inc.

USD | NASDAQ | Healthcare

ANIP Income Statement - Ani Pharmaceuticals Revenue & EPS | Ledgeburg

(in millions of USD, except per-share data)	Q1 FY 26	Q4 FY 25	Q3 FY 25	Q2 FY 25	Q1 FY 25	Q4 FY 24	Q3 FY 24	Q2 FY 24	Q1 FY 24	Q4 FY 23	Q3 FY 23	Q2 FY 23	Q1 FY 23	Q4 FY 22	Q3 FY 22	Q2 FY 22	Q1 FY 22	Q4 FY 21	Q3 FY 21	Q2 FY 21	Q1 FY 21	Q4 FY 20	Q3 FY 20	Q2 FY 20	Q1 FY 20	Q4 FY 19	Q3 FY 19	Q2 FY 19	Q1 FY 19	Q4 FY 18	Q3 FY 18	Q2 FY 18	Q1 FY 18	Q4 FY 17	Q3 FY 17	Q2 FY 17	Q1 FY 17	Q4 FY 16	Q3 FY 16	Q2 FY 16
Revenues
Revenues	237.5	247.1	227.8	211.4	197.1	190.6	148.3	138.0	137.4	131.7	131.8	116.5	106.8	94.2	83.8	73.9

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

(in millions of USD, except per-share data)	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009
Revenues
Revenues	923.7	883.4	614.4	486.8	316.4	216.1	208.5	206.5	201.6	176.8	128.6	76.3	56.0	30.1	20.4	0.4	2.5	1.3
Cost of Revenue	-	-	-	-	-	-	87.2	63.2	73.0	79.0	48.8	12.7	11.5	10.0	9.2	-	-	-
Gross Profit	-	-	-	-	-	-	121.3	143.4	128.6	97.8	79.8	63.6	44.5	20.1	11.2	-	-
Operating Expenses
Research & Development	51.7	51.7	44.6	34.3	22.3	11.4	16.0	19.8	15.4	9.1	2.9	2.9	2.7	1.7	1.2
Operating Income
Operating Income	123.8	111.1	0.6	47.0	(35.3)	(39.8)	(16.0)	16.4	35.4	28.3	20.1	32.7	20.0	0.9
Non-Operating
Interest Income	13.7	12.5	16.0	8.7	0.5	-	-	-	-	-	-	-	-	-	0.0	0.0
Tax & Net
Income Tax Expense	23.9	17.5	(3.7)	1.1	(14.8)	(13.5)	(3.4)	(2.9)	4.6	17.4	4.7	6.4	(9.4)	0.0	(0.0)
Per Share
EPS Basic	4.37	3.50	(1.04)	0.86	(3.05)	(3.40)	(1.88)	0.51	1.31	(0.09)	0.34	1.34	2.61	(0.92)	(1.27)	(3.15)
Supplementary Data
EBITDA	213.2	202.5	68.3	106.8	21.7	7.5	28.6	61.0	69.1	56.3	42.4	39.6	23.9	2.0	0.5	-

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

Operating Expenses
Research & Development	10.6	12.3	12.3	16.5	10.6	16.6	10.1	7.3	10.5	9.9	11.1	7.4	5.9	5.2	7.7	4.2	5.3	3.1	2.5	2.8	3.0	3.7	2.9	3.0	6.3	4.7	5.0	5.8	4.4	3.5	4.7	5.1	2.1	2.7	2.6	2.2	1.6	0.1	1.0	0.8
Selling General & Administrative	73.7	82.8	76.7	81.8	76.5	69.7	79.1	52.8	48.0	44.5	42.0	38.8	36.5	33.2	30.1	32.0
Selling & Marketing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General & Administrative	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation & Amortization	20.9	22.6	22.6	23.3	22.9	22.6	15.7	14.7	14.7	15.2	15.2	14.7	14.7	14.5	14.2	13.8
Amortization of Intangibles	18.7	20.3	20.4	21.1	20.7	20.4	13.9	13.0	13.0	13.4	13.3	12.8	12.8	12.6	12.5	11.9
Other Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Operating Expenses	198.6	212.3	191.6	197.5	170.9	195.0	168.9	132.9	117.1	124.9	113.9	104.1	96.9	92.4	88.8	86.8

Operating Income
Operating Income	38.9	34.8	36.2	13.9	26.2	(4.4)	(20.5)	5.2	20.3	6.7	17.9	12.4	9.9	1.8	(5.0)	(12.9)	(19.2)	(23.7)	(3.6)	(15.6)	3.0	0.3	2.8	(11.3)	(7.8)	(4.7)	7.3	9.3	4.4	11.4	10.1	7.3	6.5	7.4	9.3	7.0	4.6	1.3	7.9	5.2

Non-Operating
Interest Income	3.8	3.5	3.6	2.8	2.6	2.8	4.3	4.4	4.5	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	7.6	8.0	8.3	8.2	8.1	8.8	6.7	9.1	9.1	11.5	8.3	7.9	7.9	7.8	7.4	6.7	6.6	4.5
Income From Equity Investments	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Non-Operating Income	(0.7)	0.9	(0.9)	1.7	0.2	(1.4)	(2.5)	(0.1)	(0.0)	(0.0)	(0.0)	(0.1)	(0.0)	(0.0)	0.0	0.8	(0.1)
Pre-Tax Income	40.2	31.5	33.8	10.5	20.0	(13.8)	(31.5)	(2.3)	25.3	0.9	11.5	5.2	2.2	(5.7)	(12.2)	(18.8)

Tax & Net
Income Tax Expense	10.7	4.0	7.2	2.0	4.3	(3.5)	(7.3)	0.0	7.1	(0.2)	1.6	(1.0)	0.7	(1.5)	(3.6)	(3.9)	(5.8)	(6.7)	(2.7)	(4.0)	(0.0)	1.3	(0.4)	(1.4)	(2.9)	(2.8)	0.1	(0.7)	0.5	1.9	1.3	0.7	0.6	14.0	1.7	1.3	0.5	(0.5)	2.5	1.2
Net Income From Continuing Ops	29.5	27.5	26.6	8.5	15.7	(10.3)	(24.2)	(2.3)	18.2	1.2	9.9	6.2	1.4	(4.2)	(8.6)	(14.9)	(20.1)
Net Income From Discontinued Ops	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	29.5	27.5	26.6	8.5	15.7	(10.3)	(24.2)	(2.3)	18.2	1.2	9.9	6.2	1.4	(4.2)	(8.6)	(14.9)	(20.1)
Net Income Attributable To Parent	29.5	27.5	26.6	8.5	15.7	(10.3)	(24.2)	(2.3)	18.2	1.2	9.9	6.2	1.4	(4.2)	(8.6)	(14.9)
Less: Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Less: Preferred Dividends	0.0	0.0	0.3	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4
Net Income To Common Shareholders	29.5	27.5	26.3	8.1	15.3	(10.7)	(24.6)	(2.7)	17.8	0.7	9.5	5.8	1.0	(4.7)	(9.0)

Per Share
EPS Basic	1.31	-	1.19	0.37	0.70	-	(1.27)	(0.14)	0.84	-	0.46	0.30	0.06	-	(0.55)	(0.94)	(1.27)	-	(0.37)	(1.17)	0.01	-	0.04	(1.03)	(0.59)	-	0.32	0.55	0.04	-	0.43	0.24	0.19	-	0.41	0.23	0.10	-	0.22	0.10
EPS Diluted	1.28	-	1.13	0.36	0.69	-	(1.27)	(0.14)	0.82	-	0.45	0.29	0.06	-	(0.55)	(0.94)	(1.27)	-
Shares Basic	20.9	-	20.1	19.8	19.6	-	19.4	19.3	19.1	-	18.9	17.7	16.4	-	16.3	16.3	16.1	-
Shares Diluted	21.5	-	21.1	20.3	20.0	-	19.4	19.3	19.4	-	19.1	17.9	16.5	-	16.3	16.3	16.1	-

Supplementary Data
EBITDA	59.8	57.4	58.9	37.2	49.1	18.2	(4.8)	19.9	35.0	21.9	33.2	27.1	24.6	16.3	9.2	0.9	(4.6)	(10.0)	7.8	(4.2)	13.9	11.2	14.2	(0.1)	3.3	4.9	16.8	18.8	20.5	20.1	18.7	15.6	14.7	14.4	16.4	14.1	11.3	7.1	13.9	11.2
EBIT	38.9	34.8	36.2	13.9	26.2	(4.4)	(20.5)	5.2	20.3	6.7	17.9	12.4	9.9	1.8	(5.0)	(12.9)	(19.2)	(23.7)	(3.6)